MiCheck® Test
We have developed a prostate cancer blood test called MiCheck®. A series of clinical trials have shown it has superior specificity compared to prostate cancer blood tests that are available today.
MiCheck® fills the need for a test to assist physicians to decide whether or not a patient should proceed to a prostate biopsy following a high PSA reading.
- More specific than a PSA test – so a urologist can tell if a biopsy is really needed.
- Patients and their physicians will have confidence about what to do next.
- Patients who should get treatment for prostate cancer will get it sooner, and men whose MiCheck® results are negative can be monitored regularly.
That means:
- Fewer invasive tests – better for patients
- Lower healthcare costs – better for healthcare budgets and insurers
- More targeted testing– better for urologists and patients due to less patient anxiety, more efficient patient care, fewer infection risks
We are currently undertaking a US-based trial prior to its market launch.
%
PSA
%
MiCheck®
A Decade of Achievements
2007
Minomic formed to pursue opportunity in biomarkers based on MIL-38 monoclonal antibody
2009
Showed antibody binding to prostate cancer cells
2011
Received Venture Capital funding for commercialization
2014
Clinical validation studies for MiCheck® commenced
2016
Awarded Accelerating Commercialization grant to further product development
2017
Commenced MiCheck® Prospective Trial
2015 Eureka Prize
Excellence in Interdisciplinary Scientific Research
Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.
Address
Suite 2, Ground Floor,
75 Talavera Road,
Macquarie Park, NSW 2113,
Australia
Phone
International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here
Email
info@minomic.com
Finding Us
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.
Headquarters of Minomic
